Clinical Trials
HeartBeam Launches Pilot Study for On-Demand 12-Lead ECG Patch Aimed at Ischemia Detection
HeartBeam Inc. has initiated a pilot study for its investigational on-demand 12-lead ECG patch in coronary artery disease patients, potentially expanding ambulatory cardiac monitoring into ischemia detection within a $2 billion market.
Pipeline Maturity Reshapes Biotech Valuations as Clinical Progress Gains Weight
The biotechnology industry's valuation model is shifting from a revenue-centric approach to one that prioritizes clinical-stage progression and probability of success, with companies like Oncotelic Therapeutics exemplifying this trend.
Annovis Bio CEO to Present Multi-Protein Approach to Alzheimer's at Fierce Biotech Week 2026
Annovis Bio CEO will present the company's multi-protein targeting strategy for Alzheimer's disease at Fierce Biotech Week 2026, highlighting buntanetap's Phase 3 trial.
Oragenics Advances Phase IIa Trial for Concussion Treatment, Targeting Data Readout by 2026
Oragenics Inc. is actively enrolling patients at a second site in its Phase IIa trial for ONP-002, a potential first-in-class treatment for concussion, with a data readout expected by end of 2026.
Aclarion Expands Nociscan Use at Weill Cornell Medicine in New Trial on Disc Degeneration
Aclarion's second commercial agreement with Weill Cornell Medicine will deploy its Nociscan platform in a randomized controlled trial led by Dr. Roger Härtl, aiming to improve understanding and treatment of degenerative disc disease.
Vitamin D Supplement Found to Boost Chemotherapy Efficacy in Breast Cancer Patients
A Brazilian clinical trial reveals that daily vitamin D supplementation improves outcomes for women undergoing standard chemotherapy for breast cancer, highlighting a low-cost intervention with global implications.
CNS Pharmaceuticals Raises $22.5 Million to Advance Pipeline and Corporate Strategy
CNS Pharmaceuticals announced a $22.5 million private placement with institutional investors to fund asset acquisition and working capital, signaling a strategic push to expand its pipeline.
BioVersys Shareholders Approve All Board Proposals, Including New Board Member and Compensation Packages
BioVersys AG announced that shareholders approved all board proposals at its annual general meeting, including the re-election of directors and election of a new board member, as the company advances its lead antibiotic candidate into Phase 3 trials.
Telomir Pharmaceuticals Gains FDA Clearance for Telomir-Zn Phase 1/2 Trial in Triple-Negative Breast Cancer
Telomir Pharmaceuticals announced FDA IND clearance for Telomir-Zn to treat advanced triple-negative breast cancer, allowing a Phase 1/2 trial to proceed and marking a key step toward clinical development.
Aclarion Reports 196% Surge in Nociscan Scans, Advances Reimbursement and Clinical Trials
Aclarion's Q1 2026 results show a 196% year-over-year increase in Nociscan scan volumes, driven by clinical adoption and payer coverage, with a strong cash position and upcoming CLARITY trial data expected in late 2026.
Tonix Pharmaceuticals Advances Lyme Disease Prevention with Phase 1 Data and Plans for Phase 2 Study
Tonix Pharmaceuticals reported Phase 1 data for its Lyme disease prevention candidate TNX-4800 and announced plans for an adaptive Phase 2 field study, highlighting the unmet need for prophylactic options in the U.S.
GeoVax Advances Gedeptin Toward Phase 2 Initiation and Strategic Partnership Opportunities
GeoVax Labs outlines near-term milestones for its oncology candidate Gedeptin, including a planned Phase 2 trial in head and neck cancer, as it seeks combination therapy partnerships.
ARMR Sciences Advances Fentanyl Vaccine Toward Human Trials with Private Placement
ARMR Sciences Inc. completed a private placement financing led by Joseph Gunnar & Co. to advance its preventive fentanyl vaccine toward human trials, aiming to address the synthetic drug crisis.
Helus Pharma Partners with TARA Mind to Boost Veteran Recruitment in Phase 3 Depression Trial
Helus Pharma collaborates with TARA Mind and VETS to recruit veterans for its Phase 3 trial of HLP003 for major depressive disorder, aligning with a recent executive order on mental health.
New Molecule Shows Promise for Glioblastoma Treatment, Clinical Trial Underway
Researchers at Brown University Health have identified a molecule that may alter glioblastoma treatment, with a clinical trial planning direct surgical delivery to the tumor.
SureNano Science Advances GLP-1 Drug Candidate Toward Clinical Trials, Expands Investor Outreach
SureNano Science Ltd. is moving its lead obesity and diabetes drug GEP-44 into FDA IND-enabling studies with LabCorp while broadening investor communications through a partnership with Investor Brand Network.
Cingulate Advances ADHD Treatment Toward 2026 FDA Decision with Key Milestones
Cingulate Inc. progresses toward potential 2026 commercial launch of its ADHD treatment CTx-1301 following FDA acceptance of its New Drug Application and positive pediatric trial results, addressing a large market with unmet needs.
NRx Pharmaceuticals Receives Positive FDA Review for Ketamine ANDA, Targets 2026 Approval
NRx Pharmaceuticals has received a positive FDA review letter for its ketamine ANDA and reported a supportive meeting with FDA leadership, advancing its preservative-free ketamine product toward potential approval in summer 2026 for treating severe mental illness.
Tonix Pharmaceuticals Publishes Pharmacokinetic Study Supporting TONMYA's Mechanism for Fibromyalgia Treatment
Tonix Pharmaceuticals' peer-reviewed study demonstrates TONMYA's superior pharmacokinetic profile compared to oral cyclobenzaprine, supporting its use as the first new fibromyalgia treatment in over 15 years.
Analytical Validation Strengthens Soligenix Outlook as Pipeline Advances
A recent Zacks Small-Cap Research report highlights Soligenix's clinical progress and upcoming milestones, particularly in its phase 3 FLASH2 trial for cutaneous T-cell lymphoma treatment, reinforcing the company's strategic credibility and valuation potential.
GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial Amid Global Supply Concerns
GeoVax Labs is preparing to initiate a pivotal Phase 3 trial for its GEO-MVA vaccine in the second half of 2026, addressing critical global supply constraints for orthopoxvirus vaccines while reporting a reduced net loss of $21.5 million for 2025.
Personalized mRNA Vaccine Shows Promise in Extending Pancreatic Cancer Survival
A personalized mRNA vaccine has demonstrated potential to meaningfully extend survival for pancreatic cancer patients, according to six-year trial results presented at a major oncology conference.
Soligenix Reports Positive Interim and Comparative Data for CTCL Treatment HyBryte
Soligenix announced consistent interim response rates from its phase 3 FLASH2 study and positive comparative results for HyBryte against Valchlor in cutaneous T-cell lymphoma, highlighting progress for a disease with limited treatment options.
Combination Strategies Reshape Precision Oncology as Lixte Advances First-in-Class PP2A Inhibitor
Lixte Biotechnology's LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy, exemplifies the industry shift toward combination regimens to overcome resistance in solid tumors.
LIXTE Biotechnology Advances LB-100 as a Novel Cancer Treatment Enhancer
LIXTE Biotechnology's LB-100, a first-in-class PP2A inhibitor, aims to boost the effectiveness of existing chemotherapies and immunotherapies in hard-to-treat cancers, with ongoing clinical trials for ovarian, colon, and soft tissue sarcomas.
Soligenix Reports Encouraging Interim Data and Positive Comparative Results for CTCL Therapy
Soligenix released promising interim analysis from its phase 3 FLASH2 study and positive comparative results for HyBryte versus Valchlor, reinforcing its progress in developing treatments for cutaneous T-cell lymphoma.
Ocumetics Reports Life-Changing Six-Month Results from First-in-Human Study of Accommodating Intraocular Lens
Ocumetics Technology Corp. announced that six-month postoperative results from its first-in-human study of the Ocumetics Accommodating Intraocular Lens show continued vision improvements and meaningful quality-of-life enhancements for patients, with plans to advance to Group Two surgeries.
Lantern Pharma Seeks FDA Feedback on HARMONIC Trial Protocol Amendments for Lung Cancer Drug
Lantern Pharma has scheduled a Type C meeting with the FDA to discuss proposed changes to its Phase 2 HARMONIC trial for LP-300 in non-small cell lung cancer, focusing on EGFR Exon 21 L858R patients based on promising clinical data.
Oragenics Reports Early Progress in Phase IIa Trial of Intranasal Concussion Therapy
Oragenics Inc. has enrolled two patients and administered eight doses in its Phase IIa trial for ONP-002, a potential first-in-class intranasal treatment for mild traumatic brain injury, addressing a significant unmet medical need in a market with no FDA-approved pharmacological therapies.
Soligenix Gains European Orphan Drug Designation for Behçet's Disease Therapy SGX945
The European Commission granted orphan drug designation to Soligenix's SGX945 for treating Behçet's disease, validating the therapy's potential and providing regulatory and commercial incentives for development in a rare disease area with significant unmet need.